Literature DB >> 29210569

Modulating DNA Repair Pathways to Improve Precision Genome Engineering.

Katherine S Pawelczak1, Navnath S Gavande, Pamela S VanderVere-Carozza, John J Turchi1.   

Abstract

Programmable nucleases like the popular CRISPR/Cas9 system allow for precision genome engineering by inducing a site-specific DNA double strand break (DSB) within a genome. The DSB is repaired by endogenous DNA repair pathways, either nonhomologous end joining (NHEJ) or homology directed repair (HDR). The predominant and error-prone NHEJ pathway often results in small nucleotide insertions or deletions that can be used to construct knockout alleles. Alternatively, HDR activity can result in precise modification incorporating exogenous DNA fragments into the cut site. However, genetic recombination in mammalian systems through the HDR pathway is an inefficient process and requires cumbersome laboratory methods to identify the desired accurate insertion events. This is further compromised by the activity of the competing DNA repair pathway, NHEJ, which repairs the majority of nuclease induced DNA DSBs and also is responsible for mutagenic insertion and deletion events at off-target locations throughout the genome. Various methodologies have been developed to increase the efficiency of designer nuclease-based HDR mediated gene editing. Here, we review these advances toward modulating the activities of the two critical DNA repair pathways, HDR and NHEJ, to enhance precision genome engineering.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29210569     DOI: 10.1021/acschembio.7b00777

Source DB:  PubMed          Journal:  ACS Chem Biol        ISSN: 1554-8929            Impact factor:   5.100


  36 in total

Review 1.  Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery.

Authors:  Piotr S Kowalski; Arnab Rudra; Lei Miao; Daniel G Anderson
Journal:  Mol Ther       Date:  2019-02-19       Impact factor: 11.454

Review 2.  TIRR: a potential front runner in HDR race-hypotheses and perspectives.

Authors:  A A Anuchina; A V Lavrov; S A Smirnikhina
Journal:  Mol Biol Rep       Date:  2020-02-08       Impact factor: 2.316

Review 3.  Delivery of CRISPR-Cas9 system for screening and editing RNA binding proteins in cancer.

Authors:  Jingyue Yan; Diana D Kang; Gillian Turnbull; Yizhou Dong
Journal:  Adv Drug Deliv Rev       Date:  2021-11-09       Impact factor: 15.470

4.  Manipulating gene translation in plants by CRISPR-Cas9-mediated genome editing of upstream open reading frames.

Authors:  Xiaomin Si; Huawei Zhang; Yanpeng Wang; Kunling Chen; Caixia Gao
Journal:  Nat Protoc       Date:  2020-01-08       Impact factor: 13.491

Review 5.  Modulation of DNA double-strand break repair as a strategy to improve precise genome editing.

Authors:  Ujjayinee Ray; Sathees C Raghavan
Journal:  Oncogene       Date:  2020-09-03       Impact factor: 9.867

6.  Comprehensive optimization of a reporter assay toolbox for three distinct CRISPR-Cas systems.

Authors:  Li Chen; Haoyuan Gao; Bing Zhou; Yu Wang
Journal:  FEBS Open Bio       Date:  2021-06-09       Impact factor: 2.693

Review 7.  CRISPR-Cas guides the future of genetic engineering.

Authors:  Gavin J Knott; Jennifer A Doudna
Journal:  Science       Date:  2018-08-31       Impact factor: 47.728

Review 8.  Harnessing lipid nanoparticles for efficient CRISPR delivery.

Authors:  Jingyue Yan; Diana D Kang; Yizhou Dong
Journal:  Biomater Sci       Date:  2021-09-14       Impact factor: 7.590

9.  Harnessing accurate non-homologous end joining for efficient precise deletion in CRISPR/Cas9-mediated genome editing.

Authors:  Tao Guo; Yi-Li Feng; Jing-Jing Xiao; Qian Liu; Xiu-Na Sun; Ji-Feng Xiang; Na Kong; Si-Cheng Liu; Guo-Qiao Chen; Yue Wang; Meng-Meng Dong; Zhen Cai; Hui Lin; Xiu-Jun Cai; An-Yong Xie
Journal:  Genome Biol       Date:  2018-10-19       Impact factor: 13.583

Review 10.  Small-molecule drug repurposing to target DNA damage repair and response pathways.

Authors:  Jacqueline A Brinkman; Yue Liu; Stephen J Kron
Journal:  Semin Cancer Biol       Date:  2020-02-27       Impact factor: 15.707

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.